BACKGROUND: Bone metastasis is the most common cause of morbidity and mortality in patients with advanced prostate cancer and is manifested primarily as mixed osteoblastic and osteolytic lesions. However, the mechanisms responsible for bone metastases in prostate cancer are not clearly understood, in part due to the lack of relevant in vivo models that mimic the clinical presentation of the disease in humans. We previously established a nude mouse model with mixed bone metastases using intracardiac injection of canine prostate cancer cells (Ace-1). In this study, we hypothesized that tumor-induced osteolysis promoted the incidence of bone metastases and osteoblastic activity. METHODS: We studied the effect of inhibition of osteolysis with zoledronic acid (ZA) on the prevention and progression of Ace-1 bone metastases in nude mice using prophylactic and delayed treatment protocols. Bioluminescent imaging, radiography, and histopathological evaluation were performed to monitor the effect of ZA on the incidence, progression and nature of bone metastases. RESULTS: Unexpectedly, there was no significant difference in tumor burden and the incidence of metastasis between control and treatment groups as detected by bioluminescent imaging and bone histomorphometry. However, radiographic and histopathological analysis showed a significant treatment-related decrease in osteolysis, but no effect on tumor-induced trabecular bone thickness in both treatment groups compared to controls. CONCLUSION: Our results demonstrated that the incidence of prostate cancer bone metastases in vivo was not reduced by zoledronic acid even though zoledronic acid inhibited bone resorption and bone loss associated with the mixed osteoblastic/osteolytic bone metastases in the Ace-1 model. (c) 2008 Wiley-Liss, Inc.
BACKGROUND: Bone metastasis is the most common cause of morbidity and mortality in patients with advanced prostate cancer and is manifested primarily as mixed osteoblastic and osteolytic lesions. However, the mechanisms responsible for bone metastases in prostate cancer are not clearly understood, in part due to the lack of relevant in vivo models that mimic the clinical presentation of the disease in humans. We previously established a nude mouse model with mixed bone metastases using intracardiac injection of canineprostate cancer cells (Ace-1). In this study, we hypothesized that tumor-induced osteolysis promoted the incidence of bone metastases and osteoblastic activity. METHODS: We studied the effect of inhibition of osteolysis with zoledronic acid (ZA) on the prevention and progression of Ace-1 bone metastases in nude mice using prophylactic and delayed treatment protocols. Bioluminescent imaging, radiography, and histopathological evaluation were performed to monitor the effect of ZA on the incidence, progression and nature of bone metastases. RESULTS: Unexpectedly, there was no significant difference in tumor burden and the incidence of metastasis between control and treatment groups as detected by bioluminescent imaging and bone histomorphometry. However, radiographic and histopathological analysis showed a significant treatment-related decrease in osteolysis, but no effect on tumor-induced trabecular bone thickness in both treatment groups compared to controls. CONCLUSION: Our results demonstrated that the incidence of prostate cancer bone metastases in vivo was not reduced by zoledronic acid even though zoledronic acid inhibited bone resorption and bone loss associated with the mixed osteoblastic/osteolytic bone metastases in the Ace-1 model. (c) 2008 Wiley-Liss, Inc.
Authors: Chand Khanna; Kerstin Lindblad-Toh; David Vail; Cheryl London; Philip Bergman; Lisa Barber; Matthew Breen; Barbara Kitchell; Elizabeth McNeil; Jaime F Modiano; Steven Niemi; Kenine E Comstock; Elaine Ostrander; Susan Westmoreland; Stephen Withrow Journal: Nat Biotechnol Date: 2006-09 Impact factor: 54.908
Authors: Sandra M Axiak-Bechtel; Senthil R Kumar; Kristin K Dank; Nicole A Clarkson; Kim A Selting; Jeffrey N Bryan; Thomas J Rosol; Jahna Espinosa; Charles J Decedue Journal: Invest New Drugs Date: 2013-09-13 Impact factor: 3.850
Authors: C K Martin; W P Dirksen; M M Carlton; L G Lanigan; S P Pillai; J L Werbeck; J K Simmons; B E Hildreth; C A London; R E Toribio; T J Rosol Journal: Vet Comp Oncol Date: 2013-05-08 Impact factor: 2.613
Authors: Daniela Sicoli; Xuanmao Jiao; Xiaoming Ju; Marco Velasco-Velazquez; Adam Ertel; Sankar Addya; Zhiping Li; Sebastiano Andò; Alessandro Fatatis; Bishnuhari Paudyal; Massimo Cristofanilli; Mathew L Thakur; Michael P Lisanti; Richard G Pestell Journal: Cancer Res Date: 2014-12-01 Impact factor: 12.701
Authors: Chelsea K Martin; Wessel P Dirksen; Sherry T Shu; Jillian L Werbeck; Nanda K Thudi; Mamoru Yamaguchi; Tobie D Wolfe; Kristin N Heller; Thomas J Rosol Journal: Oral Oncol Date: 2012-01-21 Impact factor: 5.337
Authors: Lisa Y Wu; Jacqueline M Johnson; Jessica K Simmons; Desiree E Mendes; Jonathan J Geruntho; Tiancheng Liu; Wessel P Dirksen; Thomas J Rosol; William C Davis; Clifford E Berkman Journal: Prostate Date: 2014-01-21 Impact factor: 4.104
Authors: George R Schade; Jill Keller; Kim Ives; Xu Cheng; Thomas J Rosol; Evan Keller; William W Roberts Journal: J Urol Date: 2012-09-20 Impact factor: 7.450
Authors: Tobie D Wolfe; Smitha Pankajavally Somanathan Pillai; Blake Eason Hildreth; Lisa G Lanigan; Chelsea K Martin; Jillian L Werbeck; Thomas J Rosol Journal: Clin Exp Metastasis Date: 2011-03-04 Impact factor: 5.150
Authors: J K Simmons; B E Hildreth; W Supsavhad; S M Elshafae; B B Hassan; W P Dirksen; R E Toribio; T J Rosol Journal: Vet Pathol Date: 2015-05-28 Impact factor: 2.221
Authors: Joseph J Pinzone; Brett M Hall; Nanda K Thudi; Martin Vonau; Ya-Wei Qiang; Thomas J Rosol; John D Shaughnessy Journal: Blood Date: 2008-08-07 Impact factor: 22.113
Authors: Haiming Ding; Shankaran Kothandaraman; Li Gong; Michelle M Williams; Wessel P Dirksen; Thomas J Rosol; Michael F Tweedle Journal: Prostate Date: 2016-03-04 Impact factor: 4.104